ArticleFrontiers in pharmacology2022
Analysis of clinical characteristics of mesalazine-induced cardiotoxicity.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Disproportionality analysis of drug-induced myocarditis: Insights from the Food and Drug Administration Adverse Event Reporting System database.The Journal of international medical research · 2026Article
- Mesalazine-Induced Myocarditis: A Challenging Diagnostic Journey.Clinical case reports · 2026Article
- Immunomodulators, Biologics, and 5-ASA for Inflammatory Bowel Disease and Major Adverse Cardiovascular Events in Older Adults.JAMA network open · 2026Article
- Recurrent Pleuropericarditis Associated with Mesalazine Therapy Masked by Steroid Use.European journal of case reports in internal medicine · 2026Article
- Evolving Trends and Drug Class Dynamics in Drug-Induced Myocarditis: A 2-Decade Comparative Analysis of Pharmacovigilance Data.Journal of the American Heart Association · 2025Article
- Arrhythmogenic Implications of Inflammatory Bowel Disease: Its Mechanisms and Treatment Effects.Cureus · 2025Review
- Article
- Ulcerative Colitis with Acute Pericarditis after Dose Escalation of Mesalazine.Internal medicine (Tokyo, Japan) · 2025Article
- Risk of drug-induced pericardial effusion: a disproportionality analysis of the FAERS database.BMC pharmacology & toxicology · 2025Article
- Review
- Mesalazine-induced myocarditis in a patient with ulcerative colitis: a case report.European heart journal. Case reports · 2024Article
- Cardiac magnetic resonance in a rare case of recurrent mesalazine-induced myocarditis.Future cardiology · 2024Article
- Myocarditis Related to the Use of Mesalazine.Journal of medical cases · 2023Article
- Berberine Alleviates Doxorubicin-Induced Myocardial Injury and Fibrosis by Eliminating Oxidative Stress and Mitochondrial Damage via Promoting Nrf-2 Pathway Activation.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.